Integrity Applications Inc.01.12.16
Ashdod, Israel-based Integrity Applications Inc., which makes maker of Glucotrack, a non-invasive device for measuring glucose levels of people with Type 2 diabetes and pre-diabetics, has hired Eran Cohen as its chief operating officer (COO).
Cohen brings over 17 years of extensive and diversified experience in global executive roles in high growth companies in Israel and abroad. His previous positions include vice president of operations, vice president of global services and vice president of finance and operations with Nasdaq listed high-tech and medical companies. Most recently he was vice president of global services for Lumenis Ltd., a maker of laser and light based systems for aesthetic, ophthalmic, surgical and dental applications. Prior to Lumenis, Cohen served as vice president of operations at Cadent, which was acquired by Align Technologies. He has an executive MBA from Tel-Aviv University, Recanati School of Management and B.Sc. in economics and management from the Technion, Israel Institute of Technology.
“We are very pleased to announce and welcome Eran as our chief operating officer,” said CEO Avner Gal. “His operational experience, coupled with his hands on approach, will greatly benefit us as we bring the upgraded Glucotrack device to market in 2016. His position, as well as the international sales and business development manager position that we announced last month reflects our intent and preparation to aggressively execute the commercialization of our product.”
Glucotrack is a non-invasive device for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes that does not require pricking of the fingers to draw blood for daily glucose monitoring. The device features a small sensor that clips to the earlobe and measures the wearer’s glucose level by taking measurements using three technologies. The measured signals are analyzed using a proprietary algorithm and displayed on a small handheld device, the size of a mobile phone. The derived glucose measurement is also announced verbally, facilitating use by elderly and vision-impaired diabetes patients.
The Glucotrack model DF-F is expected to begin clinical trials for U.S Food and Drug Administration approval in early 2016, subject to approval of Integrity Applications’ clinical trials protocol by the agency. Model DF-F obtained a CE mark approval in June 2013 and recently received approval to market the device also to pre-diabetics. The model is currently under assessment with the China Food and Drug Administration as well as food and drug governing bodies in Japan, South Korea Canada and Australia.
Cohen brings over 17 years of extensive and diversified experience in global executive roles in high growth companies in Israel and abroad. His previous positions include vice president of operations, vice president of global services and vice president of finance and operations with Nasdaq listed high-tech and medical companies. Most recently he was vice president of global services for Lumenis Ltd., a maker of laser and light based systems for aesthetic, ophthalmic, surgical and dental applications. Prior to Lumenis, Cohen served as vice president of operations at Cadent, which was acquired by Align Technologies. He has an executive MBA from Tel-Aviv University, Recanati School of Management and B.Sc. in economics and management from the Technion, Israel Institute of Technology.
“We are very pleased to announce and welcome Eran as our chief operating officer,” said CEO Avner Gal. “His operational experience, coupled with his hands on approach, will greatly benefit us as we bring the upgraded Glucotrack device to market in 2016. His position, as well as the international sales and business development manager position that we announced last month reflects our intent and preparation to aggressively execute the commercialization of our product.”
Glucotrack is a non-invasive device for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes that does not require pricking of the fingers to draw blood for daily glucose monitoring. The device features a small sensor that clips to the earlobe and measures the wearer’s glucose level by taking measurements using three technologies. The measured signals are analyzed using a proprietary algorithm and displayed on a small handheld device, the size of a mobile phone. The derived glucose measurement is also announced verbally, facilitating use by elderly and vision-impaired diabetes patients.
The Glucotrack model DF-F is expected to begin clinical trials for U.S Food and Drug Administration approval in early 2016, subject to approval of Integrity Applications’ clinical trials protocol by the agency. Model DF-F obtained a CE mark approval in June 2013 and recently received approval to market the device also to pre-diabetics. The model is currently under assessment with the China Food and Drug Administration as well as food and drug governing bodies in Japan, South Korea Canada and Australia.